How to Buy Bridgebio Oncology Therapeutics Stock
Bridgebio Oncology Therapeutics Inc
BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company developing next-generation small molecule therapeutics targeting RAS and PI3Kα malignancies, which are prevalent oncogenes in human tumors.
Bridgebio Oncology Therapeutics stock last closed at $11.42, down 0.74% from the previous day, and has increased 7.69% in one year. It has overperformed other stocks in the Biotechnology industry by 0.45 percentage points. Bridgebio Oncology Therapeutics stock is currently +34.29% from its 52-week low of $8.50, and -23.23% from its 52-week high of $14.87.
As of Jan 16, 2026, there are 79.99M shares of BBOT outstanding. The market capitalization of BBOT is $913.07M. In the last 24 hours, 198,000 BBOT shares were traded.
How to Buy Bridgebio Oncology Therapeutics Stock
Not sure how to invest in Bridgebio Oncology Therapeutics stock? Here's how.
- Choose where to buy Bridgebio Oncology Therapeutics stock: You need to choose a stock brokerage, but don't worry - we've tried dozens of online brokerages and apps to help you decide where to buy Bridgebio Oncology Therapeutics stock.
- Create a brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've found.
- Fund your brokerage account: Choose your method of payment and add your information.
- Research Bridgebio Oncology Therapeutics stock: The Bridgebio Oncology Therapeutics ticker symbol is BBOT. Is Bridgebio Oncology Therapeutics stock a good investment? Should you buy shares of BBOT? How do BBOT's underlying business fundamentals look? Do top analysts think Bridgebio Oncology Therapeutics is a good buy? Why has BBOT's stock price moved recently? (Hint: Our stock research tools can help you decide if BBOT is a good stock to buy).
- Place your BBOT purchase: Decide if you will purchase BBOT shares at the current market price or use a limit order to purchase BBOT stock at a particular price.
- Get the latest news on your investment in BBOT: Create a watchlist to get live updates on your investment in Bridgebio Oncology Therapeutics stock.
Step 1: Choose where to buy Bridgebio Oncology Therapeutics stock
You will need a brokerage account in order to access the NASDAQ market and buy BBOT stock.
Our favorite brokerage: eToro
Based on our experience, eToro is the best place to buy stocks. eToro gives you:
- You can invest in stocks with zero commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still invest in the stock.
- Access to world markets: From Technology to Healthcare, New York to Shanghai (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's leading stock exchanges.
- Social investing: eToro has a community with more than 20 million users globally. Talk to, learn from, and copy the crypto trades of top investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other assets: Such as ETFs and cryptocurrencies.
Get $10 towards your purchase of stock by signing up for an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Create a brokerage account
Now that you've chosen the best brokerage, it's time to fill out some personal information so you are able to buy BBOT today.
How to Start a New Investment Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Enter your personal details to open your new brokerage account.
- Send your info by hitting the "Create Account" button. Get started with eToro today
Step 3: Fund your brokerage account
Now that you've filled out your info on app for stock market, your next step is to transfer the money for your investment:
Check out the tutorial below for more details transferring money into your investment account.
Step 4: Research Bridgebio Oncology Therapeutics stock
After you have selected the best place to buy Bridgebio Oncology Therapeutics stock, it's critical to evaluate their stock prior to buying, so you can understand the risk and upside.
Bridgebio Oncology Therapeutics Metrics
Fundamentals of BBOT
WallStreetZen was built to help average investors do more accurate fundamental analysis quickly.
You can see all of the due diligence checks on BBOT's stock page.
What is the fair value of BBOT stock?
Analysts use a variety of different financial metrics, analyses, models, and charts to gauge BBOT's intrinsic value.
Using relative valuations methods:
- BBOT could be undervalued based on its P/B ratio of 2.04x, relative to Biotechnology industry P/B ratio of 5.49x
You can do more valuation analysis on BBOT's stock here.
Is BBOT a healthy company?
Passed Financial Due Diligence Checks:
- There are more short-term assets than short-term liabilities on the BBOT balance sheet.
- BBOT's operating cash flow of $549.27M allows it to safely service it's debt of $2.89M.
- BBOT has a low debt to equity ratio of 0.09.
- There are more short-term assets than long-term liabilities on the BBOT balance sheet.
Failed Financial Due Diligence Checks:
- BBOT earnings of -$153.60M is not sufficient to cover its interest payments.
Is BBOT stock a Buy, Hold, or Sell, according to analysts?
Out of 6 Equities analysts who give forecasts on BBOT, the consensus analyst rating on BBOT is a Buy
It's important to note that analyst forecasts are not recommendations, nor are they investment advice.
Latest BBOT Analyst Upgrades/Downgrades
Robert Burns, a bottom 2% analyst from HC Wainwright & Co. initiates coverage on BBOT with a buy rating and announces their BBOT price target of $27.00, on Sep 15, 2025.
You can dig deeper into what analysts are saying on the Bridgebio Oncology Therapeutics stock forecast page.
BBOT Technicals
Latest Insiders Trades at BBOT
In the last 12 months, executives and large shareholders at BBOT have bought more shares than they have sold.
Bihua Chen, Director of BBOT, was the latest BBOT insider to buy. They bought $8,150,235.63 worth of BBOT stock on Aug 11, 2025.
Get more info about who owns BBOT stock here.
Can I get consistent income from BBOT stock?
No, Bridgebio Oncology Therapeutics doesn't provide an income stream by paying out dividends.
Get opinions from other investors
One of the reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to find out what other investors have to say.
Step 5: Place your BBOT purchase
There are two primary types of orders:
- Market order: A market order is an order to buy or sell a stock at the best available price.
Market orders are generally the easiest way to buy. - Limit order: A limit order is an order to buy or sell a security at a specific price (or better).
If you want to be certain you're buying or selling at an exact dollar amount, place a limit order.
Press the Open button and eToro will place the order.
If you need additional help with investing in stocks on eToro, click the how to video below:
Step 6: Get the latest news on your investment in BBOT
Now that you own some BBOT shares, you'll want to keep up with your stock purchase.
Create a watchlist to keep track of your BBOT stock.
BBOT Feed
How to Buy Stock in Bridgebio Oncology Therapeutics
To reiterate, here are the 6 steps to buy Bridgebio Oncology Therapeutics stock:
- Choose where to buy Bridgebio Oncology Therapeutics stock
- Create a brokerage account
- Fund your brokerage account
- Research Bridgebio Oncology Therapeutics stock
- Place your BBOT purchase
- Get the latest news on your investment in BBOT
If you need a brokerage, eToro is our recommended option.
Get Started with eToro TodayIf you would like to watch your investment in Bridgebio Oncology Therapeutics, create a watchlist today.
Other Content You May Like
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.